Anticoagulant
Pre-clinicalUNKNOWN 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anticoagulant-induced Bleeding
Conditions
Anticoagulant-induced Bleeding, Intracranial Hemorrhages
Trial Timeline
Aug 9, 2023 → Jan 31, 2024
NCT ID
NCT06168838About Anticoagulant
Anticoagulant is a pre-clinical stage product being developed by AstraZeneca for Anticoagulant-induced Bleeding. The current trial status is unknown. This product is registered under clinical trial identifier NCT06168838. Target conditions include Anticoagulant-induced Bleeding, Intracranial Hemorrhages.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06168838 | Pre-clinical | UNKNOWN |